179 related articles for article (PubMed ID: 34510500)
1. Secondary primary malignancies in patients with multiple myeloma: A single institution experience.
Fei F; Reddy V; Rosenblum F
Hematol Oncol; 2021 Dec; 39(5):674-679. PubMed ID: 34510500
[TBL] [Abstract][Full Text] [Related]
2. Changing trends in the risk factors for second primary malignancies after autologous stem cell transplantation for multiple myeloma before and after the introduction of proteasome inhibitors and immunomodulatory drugs.
Takamatsu H; Matsuda T; Mizuno S; Takahashi T; Fuchida SI; Hanamura I; Kataoka K; Tsukada N; Matsumoto M; Hangaishi A; Doki N; Uchida N; Sawa M; Maruyama Y; Kurahashi S; Nagafuji K; Harazaki Y; Kako S; Iida S; Ichinohe T; Kanda Y; Atsuta Y; Sunami K;
Haematologica; 2023 Dec; 108(12):3399-3408. PubMed ID: 37470160
[TBL] [Abstract][Full Text] [Related]
3. Effect of autologous hematopoietic stem cell transplant on the development of second primary malignancies in multiple myeloma patients.
Rosenberg AS; Brunson A; Tuscano J; Jonas BA; Hoeg R; Wun T; Keegan THM
Blood Cancer J; 2021 Jan; 11(1):5. PubMed ID: 33414400
[TBL] [Abstract][Full Text] [Related]
4. Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents.
Sahebi F; Iacobelli S; Sbianchi G; Koster L; Blaise D; Reményi P; Russell NH; Ljungman P; Kobbe G; Apperley J; Trneny M; Krejci M; Wiktor-Jedrzejczak W; Sanchez JF; Schaap N; Isaksson C; Lenhoff S; Browne P; Scheid C; Wilson KMO; Yakoub-Agha I; Muñiz SG; Schönland S; Morris C; Garderet L; Kröger N
Biol Blood Marrow Transplant; 2018 May; 24(5):930-936. PubMed ID: 29339268
[TBL] [Abstract][Full Text] [Related]
5. Second primary malignancies in patients with haematological cancers treated with lenalidomide: a systematic review and meta-analysis.
Saleem K; Franz J; Klem ML; Yabes JG; Boyiadzis M; Jones JR; Shaikh N; Lontos K
Lancet Haematol; 2022 Dec; 9(12):e906-e918. PubMed ID: 36354020
[TBL] [Abstract][Full Text] [Related]
6. The risk of secondary primary malignancies after therapy for multiple myeloma.
Areethamsirikul N; Reece DE
Leuk Lymphoma; 2015; 56(11):3012-21. PubMed ID: 25947036
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and outcomes of therapy-related myeloid neoplasms after treatment for multiple myeloma.
Duong VH; Holtzman NG; Koka R; Singh ZN; Zou Y; Emadi A; Rapoport AP; Kocoglu MH; Baer MR; Badros AZ
Leuk Lymphoma; 2019 Dec; 60(14):3577-3580. PubMed ID: 31282234
[No Abstract] [Full Text] [Related]
8. Second primary malignancies in multiple myeloma: A review.
Poh C; Keegan T; Rosenberg AS
Blood Rev; 2021 Mar; 46():100757. PubMed ID: 32972803
[TBL] [Abstract][Full Text] [Related]
9. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis.
Ragon BK; Shah MV; D'Souza A; Estrada-Merly N; Gowda L; George G; de Lima M; Hashmi S; Kharfan-Dabaja MA; Majhail NS; Banerjee R; Saad A; Hildebrandt GC; Mian H; Abid MB; Battiwalla M; Lekakis LJ; Patel SS; Murthy HS; Nieto Y; Strouse C; Badawy SM; Al Hadidi S; Dholaria B; Aljurf M; Vesole DH; Lee CH; Pawarode A; Gergis U; Miller KC; Holmberg LA; Afrough A; Solh M; Munshi PN; Nishihori T; Anderson LD; Wirk B; Kaur G; Qazilbash MH; Shah N; Kumar SK; Usmani SZ
Blood Adv; 2023 Jun; 7(12):2746-2757. PubMed ID: 36827681
[TBL] [Abstract][Full Text] [Related]
10. Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.
Krishnan AY; Mei M; Sun CL; Thomas SH; Teh JB; Kang T; Htut M; Somlo G; Sahebi F; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Feb; 19(2):260-5. PubMed ID: 23073267
[TBL] [Abstract][Full Text] [Related]
11. Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P; Anderson KC; Attal M; Richardson PG; Badros A; Hou J; Comenzo R; Du J; Durie BGM; San Miguel J; Einsele H; Chen WM; Garderet L; Pietrantuono G; Hillengass J; Kyle RA; Moreau P; Lahuerta JJ; Landgren O; Ludwig H; Larocca A; Mahindra A; Cavo M; Mazumder A; McCarthy PL; Nouel A; Rajkumar SV; Reiman A; Riva E; Sezer O; Terpos E; Turesson I; Usmani S; Weiss BM; Palumbo A;
Ann Oncol; 2017 Feb; 28(2):228-245. PubMed ID: 27864218
[TBL] [Abstract][Full Text] [Related]
12. Second primary malignancies in laryngeal carcinoma patients treated with definitive radiotherapy.
Ozdemir Y; Topkan E
Indian J Cancer; 2019; 56(1):29-34. PubMed ID: 30950440
[TBL] [Abstract][Full Text] [Related]
13. Secondary primary malignancies during the lenalidomide-dexamethasone regimen in relapsed/refractory multiple myeloma patients.
Kotchetkov R; Masih-Khan E; Chu CM; Atenafu EG; Chen C; Kukreti V; Trudel S; Tiedemann R; Reece DE
Cancer Med; 2017 Jan; 6(1):3-11. PubMed ID: 27860411
[TBL] [Abstract][Full Text] [Related]
14. Is the risk of second primary malignancy increased in multiple myeloma in the novel therapy era? A population-based, retrospective cohort study in Taiwan.
Liu Y; Hou HA; Qiu H; Tang CH
Sci Rep; 2020 Sep; 10(1):14393. PubMed ID: 32873831
[TBL] [Abstract][Full Text] [Related]
15. Risk of secondary primary malignancies in multiple myeloma patients with or without autologous stem cell transplantation.
Yamasaki S; Yoshimoto G; Kohno K; Henzan H; Aoki T; Tanimoto K; Sugio Y; Muta T; Kamimura T; Ohno Y; Ogawa R; Eto T; Nagafuji K; Miyamoto T; Akashi K; Iwasaki H;
Int J Hematol; 2019 Jan; 109(1):98-106. PubMed ID: 30251131
[TBL] [Abstract][Full Text] [Related]
16. Distinct patterns of occurrence, common associations, and survival of patients with second primary maligancies: A 5-year single institute experience with review of literature.
Vadgaonkar RA; Nayak SS; Doni S; Digumarti L; Mullapally SK; Digumarti R
Indian J Pathol Microbiol; 2021; 64(4):725-731. PubMed ID: 34673592
[TBL] [Abstract][Full Text] [Related]
17. Increasing therapy-related myeloid neoplasms in multiple myeloma.
Fernández-Caballero M; Salmerón D; Dolores Chirlaque M; Chen-Liang TH; Hurtado AM; García Malo MD; Ortuño FJ; Roldán V; Vicente V; Jerez A; De Arriba F
Eur J Clin Invest; 2019 Feb; 49(2):e13050. PubMed ID: 30422316
[TBL] [Abstract][Full Text] [Related]
18. Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
Fabre C; Koscielny S; Mohty M; Fegueux N; Blaise D; Maillard N; Tabrizi R; Michallet M; Socié G; Yakoub-Agha I; Garban F; Uzunov M; François S; Contentin N; Lapusan S; Bourhis JH
Haematologica; 2012 Apr; 97(4):482-90. PubMed ID: 22058218
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.
Pemmaraju N; Shah D; Kantarjian H; Orlowski RZ; Nogueras González GM; Baladandayuthapani V; Jain N; Wagner V; Garcia-Manero G; Shah J; Ravandi F; Pierce S; Takahashi K; Daver N; Nazha A; Verstovsek S; Jabbour E; De Lima M; Champlin R; Cortes J; Qazilbash MH
Clin Lymphoma Myeloma Leuk; 2015 Feb; 15(2):110-4. PubMed ID: 25107338
[TBL] [Abstract][Full Text] [Related]
20. Second primary malignancy after multiple myeloma-population trends and cause-specific mortality.
Costa LJ; Godby KN; Chhabra S; Cornell RF; Hari P; Bhatia S
Br J Haematol; 2018 Aug; 182(4):513-520. PubMed ID: 29974936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
